Raising Pharmacist Awareness of New HIV Therapies for Special Populations

Raising Pharmacist Awareness of New HIV Therapies for Special Populations
Contact: Matt Miller
Phone: 646-336-6495
Fax: 646-336-6497
Email: [email protected]

NEW YORK (10/5/2021) – DKBmed, LLC is developing a webcast to educate managed care and pharmacy professionals on advances in HIV therapies. The program, entitled Improving HIV Outcomes: Addressing Special Populations, will specifically focus on the implications of new treatments as they relate to special populations with HIV.

In the United States, approximately 1.2 million individuals live with HIV, and around 1 in 7 has not yet received a formal diagnosis. Although treatments for HIV have advanced considerably in the last decade, these developments have led to updates in guidelines and require clinicians to stay up to date on shifting recommendations. Pharmacy directors, pharmacists, and other supporting decision-makers are also challenged because special populations have particular treatment needs. Improving HIV Outcomes: Addressing Special Populations will update these key decision-makers on the latest HIV treatments to meet the diverse needs of patients. “An in-plan physician may treat around 50 patients per month with a certain condition, whereas a managed care or pharmacy professional has the potential to influence hundreds of in-plan physicians, and by extension, tens of thousands of covered patients” notes Cindy Zoellner, PharmD, BCPS-AQID, AAHIVP from UTSW Medical Center at Dallas. “Educating these members of the health care system is essential as we seek to end the HIV epidemic.”

Improving HIV Outcomes: Addressing Special Populations provides a comprehensive overview of the pharmacist’s role in the management of special populations of HIV, and how the needs of these populations will inform treatment. Many factors should be considered when selecting an HIV treatment regimen, including potential side effects and drug-drug interactions, anticipated medication adherence, long-term toxicities, baseline treatment resistance, and potential for pregnancy. Pharmacists should be aware of special considerations and challenges for treating certain populations (eg, children, transgender individuals, people with comorbidities). Specific topics of the presentation include:

  • Guidelines on initial ART regimens – how special populations may diverge from recommendations
  • Women and rapid treatment initiation – how hormonal birth control and pregnancy planning can inform treatment
  • Addressing adherence and challenges in youth and young adults
  • Balancing the needs of transgender people
  • Addressing challenges in treating HIV among patients who inject drugs
  • Current evidence and indications for newer HIV therapies

About DKBmed

DKBmed is an integrated continuing medical education company operated by an experienced team of medical education experts. DKBmed provides health care professionals with effective medical education that closes identified knowledge and practice gaps to improve patient health.

Working with accredited providers and other partners, DKBmed develops innovative educational programs and quality improvement (QI) initiatives, bringing new learning methodologies to the CME landscape. DKBmed has become a leader in QI in the independent medical education space with QI projects in Pain Management, HIV, Depression, Influenza, and Diabetic Eye Disease. DKBmed was also an early adopter of case scenarios with real patients and live actors, TED/DKBmed Talks, 3D animation, webcasts, podcasts, and smart phone applications for clinicians and patients. These forward-thinking approaches enable health care professionals to learn and access educational programs in a manner that is most convenient and appropriate for them.

DKBmed’s programs are accessible through the company’s website (www.dkbmed.com). They reach more than 150,000 health care professionals in primary care and in a variety of specialties and disease states including: HIV, COVID-19, cystic fibrosis, diabetes, influenza, dermatology, retinal disease, rheumatoid arthritis, COPD, asthma, multiple sclerosis, pain management, depression and viral hepatitis (HBV, HCV) and oncology.